Virax Biolabs Group Ltd (VRAX) Equity Ratio (2021 - 2025)

Virax Biolabs (VRAX) has 4 years of Equity Ratio data on file, last reported at 0.89 in Q1 2025.

• In Q1 2025, Equity Ratio fell 5.42% year-over-year to 0.89; the TTM figure through Mar 2025 stood at 0.26 (changed N/A YoY), while the FY2025 annual figure was 0.89, down 5.42% from the prior year.
• Equity Ratio declined to 0.89 in Q1 2025, from 0.94 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.94 in Q1 2024 and bottomed at 20.99 in Q1 2021.
• A 4-year average of 4.57 and a median of 0.9 in 2023 frame the typical range for Equity Ratio.
• Annual changes were most pronounced in 2024 — Equity Ratio climbed 3.27% — and 2025, when it dropped 5.42%.
• Year by year, Equity Ratio stood at 20.99 in 2021, then soared by 104.32% to 0.91 in 2023, then rose by 3.27% to 0.94 in 2024, then fell by 5.42% to 0.89 in 2025.
• The last three Equity Ratio figures came in at 0.89 (Q1 2025), 0.94 (Q1 2024), and 0.91 (Q1 2023), per Business Quant data.

Peer Comparison